Metal complexes constitute an attractive class of compounds for applications in medicinal chemistry and chemical biology due to features such as unusual reactivities, tunable ligand exchange kinetics, stereochemical diversity, structural complexity, the availability of radioisotopes, and distinct physicochemical properties. [1] However, it is remarkable that although the discovery of the antiproliferative activity of cis-[PtCl 2 (NH 3) 2 ] dates back almost half a century, [2] cisplatin and its derivatives remain the most important metal-based anticancer drugs used in the clinic at the present day. [3] In the quest for a new generation of metal-containing anticancer agents we here wish to report a class of rhenium(I) complexes as highly potent visible-light-triggered anticancer organometallics. We discovered that rhenium(I) indolato complexes 1-3 provoke a strong light-induced antiproliferative activity in cancer cells (Figure 1). This is unexpected since the related class of rhenium(I) tricarbonyl polypyridine complexes (e.g. 4) are well-established nontoxic luminescent probes routinely applied for biological imaging. [4] Thus, replacing just the 2,2′bipyridine in 4 for 2-(2′-pyridyl)indolato and its derivatives (1-3) completely changes the physicochemical and biological properties of such rhenium(I) complexes by abolishing luminescence and instead causing light-induced anticancer activity. [5] Figure 2 displays the structure of a benzylated derivative of rhenium(I) complex 1 in which rhenium is coordinated in a bidentate fashion to a pyrido[2,3-a]pyrrolo